Comprehensive Update of the New and Emerging Therapies for the Treatment of Multiple Myeloma
GlaxoSmithKline, Takeda Oncology, Karyopharm, and Amgen.
Faculty Presenter
Brandon R. Shank, PharmD, MPH, BCOP
Clinical Pharmacy Specialist
University of Texas MD Anderson Cancer Center
Houston, Texas
Program Description
Multiple myeloma (MM) accounts for about 1.8% of all cancers and 15% of hematologic malignancies in the United States. Although it is rarely curable, MM is a highly manageable disease that has seen rapid medical advancement over the past decade with the advent of multiple oral agents and monoclonal antibodies as well as the use of these agents within combination regimens. This program will explore current and emerging treatment of MM, including preferred combination regimens and management of therapy-induced adverse effects. This program will also address specific practices to optimize patient education and adherence for individuals receiving treatment for MM.
Target audience: Health-system pharmacists, specialty pharmacists, and oncology pharmacists
Type of activity: Application
Release date: December 2, 2020
Expiration date: June 2, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate the mechanisms of action for the new and emerging drug classes used for the treatment of multiple myeloma and the associated dosage forms of those medications
- Determine appropriate drug therapy for a patient with relapsed or refractory disease based on prior treatment regimens and patient-specific factors
- Construct a management strategy to improve adherence for a patient receiving a combination of oral and intravenous therapies for the treatment of multiple myeloma
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-382-H01-P. The activity is available for CE credit through June 2, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Brandon R. Shank, PharmD, MPH, BCOP, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Meg Taylor, PharmD, CPP; Kelly McCormick; Susan Pordon; and Brianna Winters have no financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
